Glenmark launches RYALTRIS nasal spray in Brazil for allergic rhinitis
The launch follows ANVISA approval and introduces an olopatadine-containing intranasal combination therapy in Brazil
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Glenmark Pharmaceuticals
Glenmark launches Calcium Gluconate Injection USP in US
Glenmark introduces three Calcium Gluconate Injection USP presentations for the US market
Glenmark receives USFDA approval for Fluticasone Propionate Nasal Spray
Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to Flonase Nasal Spray
Glenmark launches Methylene Blue Injection USP in US
Generic injectable approved as bioequivalent to ProvayBlue Injection 50 mg/10 mL
Glenmark launches Winlevi for acne vulgaris across European markets
Launch follows European Commission authorisation and expands availability of clascoterone cream for adults and adolescents in…
Glenmark to manage end-to-end commercialisation and distribution for RYALTRIS in US
RYALTRIS is Glenmark’s first innovative product introduced into the US market
Glenmark launches Epinephrine Injection USP multiple-dose vial in the US
Product introduced for institutional channel in the US market
Glenmark Pharmaceuticals receives EIR from US FDA for its Monroe facility
Glenmark Pharmaceuticals, a research-led, global pharmaceutical company announced that it has received the Establishment…
Glenmark Specialty secures NMPA approval for RYALTRIS nasal spray
Commercialisation to be undertaken by Grand Pharmaceuticals under existing exclusive licensing agreement
Glenmark to launch Ropivacaine Hydrochloride Injection USP in the US
Marc Kikuchi, President & Business Head, North America, highlights the new addition to Glenmark’s injectable portfolio and…